PBYI Puma Biotechnology Inc

8.51
+0.17  (+2%)
Previous Close 8.34
Open 8.38
Price To Book 19.33
Market Cap 333,396,000
Shares 39,200,000
Volume 614,083
Short Ratio
Av. Daily Volume 1,778,160
Stock charts supplied by TradingView

NewsSee all news

  1. Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that its Chief Executive Officer and President, Alan H. Auerbach, will be presenting at the 38th Annual J.P. Morgan Healthcare Conference at

  2. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on January 8, 2020 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit

  3. Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 12:00

  4. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on November 1, 2019 and December 2, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement

  5. Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2019 San Antonio Breast Cancer Symposium (SABCS)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released at ASCO June 3, 2017.
Neratinib
HER2-positive metastatic breast cancer patients with brain metastases
Phase 2 biomarker data released December 7, 2016.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 additional data released at SABCS December 11, 2019. 53% ORR (all partial responses). PFS 9.8 months. Further data 4Q 2020.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 further data due 4Q 2020.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
PDUFA date late-April 2020.
Neratinib - NALA
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
Approval announced July 17, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval.
Neratinib (NERLYNX)
Extended adjuvant HER2-positive early stage breast cancer
Phase 1/2 interim data presented at ASCO June 2018. 9 PRs, 3CRs out of 20 patients.
Neratinib plus Kadcyla (T-DM1)
HER2-positive metastatic breast cancer

Latest News

  1. Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that its Chief Executive Officer and President, Alan H. Auerbach, will be presenting at the 38th Annual J.P. Morgan Healthcare Conference at

  2. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on January 8, 2020 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit

  3. Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 12:00

  4. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on November 1, 2019 and December 2, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement

  5. Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2019 San Antonio Breast Cancer Symposium (SABCS)

  6. plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that its collaborators at The Institute of Cancer Research, London, presented results from the cohort of patients in the plasmaMATCH trial

  7. Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2019 San Antonio Breast Cancer

  8. Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX® (neratinib) in Singapore from the

  9. Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, and Pierre Fabre have agreed to extend the terms of the license agreement in which Puma granted Pierre Fabre exclusive rights to develop and

  10. Puma Biotechnology Reports Third Quarter 2019 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for the third quarter 2019

  11. Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer

    Puma Biotechnology, Inc. (NASDAQ:PBYI) announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in Hong Kong to market

  12. Puma Biotechnology to Present at the Credit Suisse Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:55

  13. Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Wednesday, November 6, 2019 following release of its third quarter 2019 financial

  14. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on October 1, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit

  15. FDA Approves Labeling Supplement for Puma Biotechnology's NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

    Interim data from the Phase II CONTROL Trial showed that the addition of prophylactic treatment with loperamide plus budesonide reduced the rate of discontinuation due to neratinib-associated diarrhea to 11% versus a

  16. Puma Biotechnology to Present at Cantor Global Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 2:25

  17. Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) for neratinib in

  18. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on September 4, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit

  19. Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer

    First regulatory approval of NERLYNX in Latin America. NERLYNX is the first approved therapy to reduce the risk of invasive disease recurrence in HER2-positive breast cancer patients following trastuzumab-based

  20. Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:35

  21. FDA Grants Orphan Drug Designation to Puma Biotechnology's NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases

    Puma Biotechnology, Inc. (NASDAQ:PBYI) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NERLYNX® (neratinib) for the treatment of breast cancer patients with brain